Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: monoclonal antibody biosimilars - XBiotech

Next Previous
Drug Profile

Research programme: monoclonal antibody biosimilars - XBiotech

Alternative Names: Cancer monoclonal antibody biosimilar - XBiotech; Inflammation monoclonal antibody biosimilar - XBiotech

Latest Information Update: 27 Apr 2017

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator XBiotech
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Cancer; Inflammation

Most Recent Events

  • 16 Mar 2017 XBiotech has patent allowance for the administration of anti-interleukin-1 alpha antibodies to treat inflammatory skin diseases and psychiatric disorders in Australia
  • 16 Mar 2017 XBiotech has patent protection for the administration of anti-interleukin-1 alpha antibodies for the treatment of cancer in Australia, New Zealand, Philippines, Singapore, and South Africa
  • 16 Mar 2017 XBiotech has patent protection for the development of interleukin-1 alpha specific monoclonal antibodies in Australia, Chile, China, Europe, Hong Kong, Indonesia, Israel, Japan, South Korea, Malaysia, Mexico, New Zealand, Philippines, Russia, Singapore, South Africa and USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top